Compare Allstate Corp (ALL) vs McKesson Corporation (MCK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allstate Corp vs McKesson Corporation — how do they compare? Allstate Corp trades at $252.97 (market cap $64.77B), while McKesson Corporation trades at $809.88 (market cap $94.36B). The key difference: McKesson Corporation is the larger of the two by market cap, and Allstate Corp pays the higher dividend (1.72%). Which is the better fit depends on your goals.
| ALL | MCK | |
|---|---|---|
Market Cap | $64.77B | $94.36B |
Sector | Financials | Health |
52-Week High | $251.61 | $995.69 |
52-Week Low | $190.00 | $659.01 |
Enterprise Value | $73.56B | $99.00B |
Dividend Yield | 1.72% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
McKesson (MCK) trades at $805.96, up 1.66% with strong bullish momentum near its pivot point of $799. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations, and revenue growth accelerating to $359.05B in 2025. Analyst sentiment is overwhelmingly positive with an 80% buy rating and a $932.83 consensus price target, while recent corporate developments include a strategic investment in Medical-Surgical Solutions with Apollo Funds.
The outlook remains favorable given robust cash flow generation and expanding profitability, though risks include policy uncertainties and high leverage. Upside potential is supported by valuation discounts relative to sector peers and continued execution in specialty pharma and oncology services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
